Literature DB >> 12763000

Molecular defects in the pathogenesis of pituitary tumours.

Andy Levy1, Stafford Lightman.   

Abstract

The majority of pituitary adenomas are trophically stable and change relatively little in size over many years. A comparatively small proportion behave more aggressively and come to clinical attention through inappropriate hormone secretion or adverse effects on surrounding structures. True malignant behaviour with metastatic spread is very atypical. Pituitary adenomas that come to surgery are predominantly monoclonal in origin and roughly half are aneuploid, indicating either ongoing genetic instability or transition through a period of genetic instability at some time during their development. Few are associated with the classical mechanisms of tumour formation but it is generally believed that the majority harbour quantitative if not qualitative differences in molecular composition compared to the normal pituitary. Despite their prevalence and the ready availability of biopsy material, at the present time, the precise molecular pathogenesis of the majority of pituitary adenomas remains unclear. This review summarizes current thinking.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12763000     DOI: 10.1016/s0091-3022(03)00012-8

Source DB:  PubMed          Journal:  Front Neuroendocrinol        ISSN: 0091-3022            Impact factor:   8.606


  16 in total

Review 1.  Pituitary disease: presentation, diagnosis, and management.

Authors:  A Levy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-09       Impact factor: 10.154

Review 2.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

3.  Patterns of gene expression in pituitary carcinomas and adenomas analyzed by high-density oligonucleotide arrays, reverse transcriptase-quantitative PCR, and protein expression.

Authors:  Katharina H Ruebel; Alexey A Leontovich; Long Jin; Gail A Stilling; Heyu Zhang; Xiang Qian; Nobuki Nakamura; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

Review 4.  Genesis of prolactinomas: studies using estrogen-treated animals.

Authors:  Dipak K Sarkar
Journal:  Front Horm Res       Date:  2006       Impact factor: 2.606

Review 5.  Epidemiology and etiopathogenesis of pituitary adenomas.

Authors:  Elena D Aflorei; Márta Korbonits
Journal:  J Neurooncol       Date:  2014-01-31       Impact factor: 4.130

Review 6.  Gene therapy for pituitary tumors.

Authors:  Adriana Seilicovich; Daniel Pisera; Sandra A Sciascia; Marianela Candolfi; Mariana Puntel; Weidong Xiong; Gabriela Jaita; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

Review 7.  Pituitary senescence: the evolving role of Pttg.

Authors:  Vera Chesnokova; Shlomo Melmed
Journal:  Mol Cell Endocrinol       Date:  2010-02-12       Impact factor: 4.102

Review 8.  Mechanisms for pituitary tumorigenesis: the plastic pituitary.

Authors:  Shlomo Melmed
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

9.  Growth hormone is a cellular senescence target in pituitary and nonpituitary cells.

Authors:  Vera Chesnokova; Cuiqi Zhou; Anat Ben-Shlomo; Svetlana Zonis; Yuji Tani; Song-Guang Ren; Shlomo Melmed
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-12       Impact factor: 11.205

10.  Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations.

Authors:  R M Ruggeri; L Santarpia; L Curtò; M L Torre; M Galatioto; S Galatioto; F Trimarchi; S Cannavò
Journal:  J Endocrinol Invest       Date:  2008-11       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.